- Home
- MQY vs AUTL Comparison
MQY vs AUTL Comparison
Compare MQY & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MQY
- AUTL
- Stock Information
- Founded
- MQY 1994
- AUTL 2014
- Country
- MQY United States
- AUTL United Kingdom
- Employees
- MQY N/A
- AUTL N/A
- Industry
- MQY Investment Bankers/Brokers/Service
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MQY Finance
- AUTL Health Care
- Exchange
- MQY Nasdaq
- AUTL Nasdaq
- Market Cap
- MQY 776.5M
- AUTL 625.4M
- IPO Year
- MQY N/A
- AUTL 2018
- Fundamental
- Price
- MQY $11.81
- AUTL $1.36
- Analyst Decision
- MQY
- AUTL Strong Buy
- Analyst Count
- MQY 0
- AUTL 5
- Target Price
- MQY N/A
- AUTL $9.12
- AVG Volume (30 Days)
- MQY 184.8K
- AUTL 4.5M
- Earning Date
- MQY 01-01-0001
- AUTL 11-11-2025
- Dividend Yield
- MQY 4.73%
- AUTL N/A
- EPS Growth
- MQY N/A
- AUTL N/A
- EPS
- MQY N/A
- AUTL N/A
- Revenue
- MQY N/A
- AUTL $29,934,000.00
- Revenue This Year
- MQY N/A
- AUTL $641.63
- Revenue Next Year
- MQY N/A
- AUTL $109.21
- P/E Ratio
- MQY N/A
- AUTL N/A
- Revenue Growth
- MQY N/A
- AUTL 185.17
- 52 Week Low
- MQY $9.82
- AUTL $1.11
- 52 Week High
- MQY $12.52
- AUTL $5.00
- Technical
- Relative Strength Index (RSI)
- MQY 81.27
- AUTL 33.35
- Support Level
- MQY $10.85
- AUTL $1.26
- Resistance Level
- MQY $11.86
- AUTL $1.46
- Average True Range (ATR)
- MQY 0.10
- AUTL 0.09
- MACD
- MQY 0.06
- AUTL 0.01
- Stochastic Oscillator
- MQY 94.51
- AUTL 30.49
About MQY Blackrock MuniYield Quality Fund Inc.
Blackrock Muniyield Quality Fund Inc is a closed-end management investment company. The company's objective is to provide shareholders with as high a level of current income exempt from U.S. federal income taxes as is consistent with its investment policies and prudent investment management. The company invests in Transportation, Corporate, Health, Utilities, Education, Housing, and other sectors.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.